Diabetes can be dangerous – especially when the disease is not diagnosed in time. Munich scientists of Helmholtz Zentrum München and Technische Universität München have identified new markers which enable an early diagnosis and prognosis of type 1 diabetes.
Under the direction of Prof. Dr. Anette Ziegler, scientists of the Diabetes Research Group at Helmholtz Zentrum München and Technische Universität München investigated the formation of antibodies to a zinc transporter in children with elevated risk for type 1 diabetes. The study provided indications of an early onset of the disease when specific antibodies in the blood and specific variants of the associated zinc transporter are present in the genome. These high-risk individuals require especially careful monitoring.
Throughout the world the number of children who develop type 1 diabetes is increasing. In Germany approximately 11,000 children are affected. On average they are eight and a half years old when they are diagnosed with the disease. However, already at this age many children show severe metabolic decompensation. Successful prevention strategies and detailed screening can prevent this.
Prof. Dr. Anette Ziegler and Dr. Peter Achenbach of Helmholtz Zentrum München and Technische Universität München in cooperation with Prof. Dr. Ezio Bonifacio of Technische Universität Dresden have developed a new approach to improve and extend risk screening. “Acute severe complications such as diabetic coma at disease onset can thus be avoided in the majority of the children,” Dr. Peter Achenbach explained. The scientists evaluated the data of 1,633 children who had at least one type 1 diabetic parent. These children’s risk for diabetes was elevated in comparison with children who had no family history of diabetes.
Genetic factors play a significant role in the development of type 1 diabetes. The scientists were able to show that specific variants of the zinc transporter gene SLC30A8 influence the risk for diabetes. The body needs this gene in order to produce ZnT8. This protein influences the zinc transport into the beta cells and plays a crucial role in their maturation and thus also in insulin secretion.
Beta cells of the islets of Langerhans in the pancreas secrete the vitally important insulin. Already prior to the onset of type 1 diabetes the body’s own immune system destroys the beta cells. If this destruction exceeds a certain threshold, the disease becomes manifest: The insulin deficiency leads to various metabolic disturbances, including elevated blood glucose levels.
“Autoantibodies to ZnT8 in combination with a specific variant of the zinc transporter gene were associated with an elevated diabetes risk,” said Dr. Peter Achenbach of the Institute for Diabetes Research. “Eighty-one percent of these children with ZnT8 antibodies developed diabetes mellitus.” A heightened diabetes risk has long been associated with the islet autoantibodies. These include the autoantibodies to insulin (IAA), islet cell antibodies to the enzyme glutamate decarboxylase (GADA) and to tyrosine phosphatases (IA-2A and IA-2ß).
“Autoantibodies to ZnT8 are an additional important marker for the progression of diabetes – especially in children who are already developing islet autoantibodies,” said PD Dr. Thomas Illig of the Institute of Epidemiology. A differentiated analysis of all autoantibodies allows the prognosis of how fast the disease will become manifest. The rule of thumb is: The larger the number of different kinds of autoantibodies, the higher the risk for diabetes, and the younger the child with autoantibodies, the earlier disease onset will be.
The above post is reprinted from materials provided by Helmholtz Zentrum Muenchen - German Research Centre for Environmental Health. Note: Materials may be edited for content and length.
Cite This Page: